Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | SOCS2 |
| Gene Name: | SOCS2 |
| Protein Full Name: | Suppressor of cytokine signaling 2 |
| Alias: | Cytokine-inducible SH2 protein 2;STAT-induced STAT inhibitor 2 |
| Mass (Da): | 22172 |
| Number AA: | 198 |
| UniProt ID: | O14508 |
| Locus ID: | 8835 |
| COSMIC ID: | SOCS2 |
| Gene location on chromosome: | 12q21.33 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 20337 |
| Percent of cancer specimens with mutations: | 0.19 |
| Gene undergoes hypermethylation: | Ovarian- and breast cancer |
| Normal role description: | SOCS2 is a cytokine-inducible negative regulator of cytokine signalling. Its expression can be induced by a subset of cytokines, including EPO, GM-CSF, IL-10 and IFNγ. SOCS2 has been found to interact with the cytoplasmic domain of the IGF1R, and is hence thought to be involved in the regulation of IGF1R-mediated cell signalling. Polymorphisms of the gene have been in implicated in Diabetes Type II susceptibility, and it has been found to be down-regulated in certain cancers, such as breast and ovarian cancer. SOCS2 has also been found to induce the differentiation of C2C12 mesenchymal cells into myoblasts or osteoblasts, and SOCS2 negative mice have been observed to have a reduced volumetric bone mineral density. Furthermore, it has been found to play an important role in neuronal development, growth, and stem cell differentiation. |
| Commentary on involvement of protein in cancer: | 1/145 lung- and 1/59 ovarian cancer samples were mutated (Sanger COSMIC) |